Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06514144 · ClinicalTrials.gov registry record
Exacerbations Among Patients Receiving Breztri (EROS Study)
A clinical trial of Pulmonary Disease and Chronic Obstructive, sponsored by AstraZeneca.
- Completed
- Registry status
- 2,409
- Enrollment target
- 1
- Study location
NCT06514144 is a study of Pulmonary Disease and Chronic Obstructive that has completed, run by AstraZeneca. The registered enrollment target is 2,409 participants, above the 498-participant average among 19 other Pulmonary Disease trials with a reported enrollment target (384% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06514144, a study of Pulmonary Disease and Chronic Obstructive, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 2,409 participants
- Enrollment target
- 1
- Study location
Study Summary
EROS was a retrospective analysis of people with COPD using the MORE2 Registry®. Inclusion required ≥1 severe, ≥2 moderate, or ≥1 moderate exacerbation while on other maintenance treatment. Primary outcomes were the rate of COPD exacerbations and healthcare costs for those that received BGF promptly. The effect of each 30-day delay in initiation of BGF was estimated using a multivariable negative binomial regression model.
Conditions Studied
Interventions
- DRUG BGF
Study Locations (1)
Delaware
- AstraZeneca - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,409 participants |
| Start Date | 2022-10-01 |
| Est. Completion | 2023-03-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06514144
The ClinicalTrials.gov registry entry for NCT06514144 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,409 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 498-participant average among 19 other Pulmonary Disease trials with a reported enrollment target (384% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which BGF is the first listed.
NCT06514144 reports 1 study location spanning 1 distinct geographic area - top geographies include Delaware.
Frequently Asked Questions
What is clinical trial NCT06514144 about?
NCT06514144 is a clinical study titled "Exacerbations Among Patients Receiving Breztri (EROS Study)". EROS was a retrospective analysis of people with COPD using the MORE2 Registry®. Inclusion required ≥1 severe, ≥2 moderate, or ≥1 moderate exacerbation while on other maintenance treatment. Primary outcomes were the rate of COPD exacerbations and healthcare costs for those that received BGF promptly...
What is the current status of trial NCT06514144?
This trial is currently completed. The enrollment target is 2,409 participants. The study started on 2022-10-01. Estimated completion is 2023-03-07.
What conditions does trial NCT06514144 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive, Retrospective Studies.
What interventions are being tested in trial NCT06514144?
The interventions under investigation include: BGF (DRUG).
Who is sponsoring clinical trial NCT06514144?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06514144 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections
RECRUITING
-
Quantitative Pulmonary Imaging Registry & Biorepository
RECRUITING
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
Study of Lung Proteins in Patients With Pneumonia
RECRUITING
-
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
RECRUITING
-
Risk Underlying Rural Areas Longitudinal Cohort Study (RURAL) Heart and Lung Study
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.